Related Experiment Videos
Lipoatrophy revisited
M L Reitman1, E Arioglu, O Gavrilova
1Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 8N-250, 10 Center Drive, Bethesda, MD 20892-1770, USA. mlr@helix.nih.gov
Trends in Endocrinology and Metabolism: TEM
|November 25, 2000
Summary
Lipoatrophy syndromes, a lack of body fat, cause insulin-resistant diabetes. Research shows this diabetes stems from fat loss, with leptin deficiency playing a role. Treatments like thiazolidinediones show promise.
Area of Science:
- Endocrinology
- Metabolic disorders
- Genetics
Background:
- Lipoatrophy syndromes are characterized by a significant paucity of adipose tissue.
- Severe lipoatrophy is strongly associated with insulin-resistant diabetes mellitus (DM).
- Etiologies for adipose tissue loss include genetic, immune, or infectious/drug-associated factors.
Purpose of the Study:
- To investigate the mechanisms linking lipoatrophy to diabetes mellitus.
- To explore the role of leptin deficiency in lipoatrophic diabetes.
- To evaluate therapeutic strategies for metabolic control in lipoatrophy.
Main Methods:
- Identification of causative mutations in Dunnigan-type familial partial lipodystrophy.
- Experimental studies using lipoatrophic mouse models.
- Clinical assessment of metabolic control with thiazolidinedione therapy.
Main Results:
- Experiments confirmed that diabetes in lipoatrophic mice results from fat loss.
- Leptin deficiency was identified as a contributing factor to the diabetes.
- Thiazolidinedione therapy demonstrated efficacy in improving metabolic control.
Conclusions:
- The study elucidates the link between adipose tissue deficiency and insulin resistance.
- Leptin plays a crucial role in the metabolic complications of lipoatrophy.
- Pharmacological interventions can improve metabolic outcomes in patients with lipoatrophy.